GlobeNewsWire
14 Jun 2026, 22:05 UTC · 22w ago
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Impact · against what's priced in
ZYME is positive following Phase 1 data for ZW191 showing high efficacy in platinum-resistant ovarian cancer and unexpected activity in FRα-negative tumors. While Grade ≥3 adverse events are high at 55%, the strong response rates and expansion of the addressable patient population provide a material valuation catalyst.
- ZYME+0.60
No priced-in read yet





